Table 3.

PSA and aspirin association across age, biopsy outcome, and prostate volume.

		Aspirin		No Aspirin
		n	PSA*	n	PSA	p-diff**
Age (years)	40 - <50	3	14.9	45	15.1	0.98
	50 - <60	72	7.9	220	8.1	0.77
	60 - <70	209	6.6	309	7.4	0.07
	70 - <80	148	7.5	196	8.5	0.11
	80 - ≤90	36	8.1	39	8.7	0.76
			p-int*** = 0.82
Biopsy Status&	Negative	233	5.6	405	5.7	0.64
	PIN	53	5.0	95	5.9	0.09
	Cancer	173	6.1	291	7.3	0.02
	Gleason 6	99	4.8	160	5.7	0.01
	Gleason 7–10	74	14.9	131	16.2	0.56
			p-int = 0.09
Volume (mls)	Less than 40	175	6.5	370	7.2	0.13
	40 - <60	160	7.5	249	7.6	0.87
	60 or more	133	8.6	190	9.7	0.06
			p-int = <0.01

^*Adjusted for age, race family history, biopsy outcome, prostate volume, BMI, WHR, number of prior PSA tests, and treatment for BPH, CVD, hyperlipidemia, and diabetes. Excluded 24 subjects with atypia or other suspicious findings from analysis.

^**p-value for difference in PSA levels between aspirin users and aspirin non-use within each stratum.

^***p-value for interaction to evaluate if the association between aspirin and PSA is similar across strata.